Tag Archives: CBT Advisors
VC From Both Sides: “Mastering the VC Game” by Jeffrey Bussgang
How rare is this? A new book offering reams of sound advice on raising money from VCs. Rarer still: a book actually written by a VC who has made money both as a VC and as an entrepreneur. Jeffrey Bussgang, a general partner at Flybridge Capital Partners, is that VC and Mastering the VC Game is his book. Read the review on http://bostonbiotechwatch.com. Continue reading
Filed under Uncategorized
Company Serves New Genetic Testing Market: The Not-Yet-Conceived
By Steve Dickman, CEO, CBT Advisors What’s the next key population for personalized medicine? We’ve got it: not those with hereditary disease nor those with chronic conditions. Not even anyone who is sick, well, young or old. It’s the not-yet-conceived. … Continue reading
Filed under Uncategorized
Networking Your Medication
Some iPhone apps have shown that mobile phones are potentially fantastic tools for one-way or two-way transmission of medical information. But actual digital pills!!?? Sure enough: at last week’s JP Morgan healthcare conference, Novartis announced a $24 million deal with Proteus Biomedical, a Bay Area, VC- and private-equity-backed maker of “smart pills” carrying embedded sensors that transmit their status (“Patient just ingested me”) to a phone and then to medical professionals via a wireless network. Boston Biotech Watch has the story. Continue reading
Filed under Uncategorized
Medicine Gets Personal – But How Do VCs Make Money?
Venture investors are warming to the idea of doing deals in “personalized medicine” – diagnostic tests, often based on genetics, that could improve outcomes and lower costs. But regulatory and reimbursement hurdles are the norm, not the exception. Nonetheless, some deals such as Highland Capital’s portfolio company Generation Health, appear very attractive. Continue reading
Filed under Uncategorized
Great week for Spiegelmers, other nucleic acid drugs points to brighter future
Great week for Spiegelmers, other nucleic acid drugs points to brighter future by Steven Dickman, CEO, CBT Advisors Spiegelmers, the new drug class consisting of mirror-image aptamers created by Germany’s NOXXON Pharma, achieved an important clinical milestone this week. The … Continue reading
Filed under Uncategorized
